GlaxoSmithKline: Streptococcal Infections trials

The registry lists 64 Streptococcal Infections studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 44 have results posted.

Phase 1 5Phase 2 10Phase 3 38Phase 4 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young AdultsRecruitingNCT07085702Phase 1
• A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy InfantsCompletedNCT05412030Phase 2Results posted
• Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.CompletedNCT02838407Not applicableResults posted
• A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy InfantsCompletedNCT02447432Phase 3Results posted
• Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent VaccineCompletedNCT02270944Phase 2Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal InfectionCompletedNCT01746108Phase 3Results posted
• Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™CompletedNCT01641133Phase 3Results posted
• Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy InfantsCompletedNCT01616459Phase 2Results posted
• Evaluation of a Vaccine for Reducing Ear and Lung Infections in ChildrenCompletedNCT01545375Phase 2Results posted
• Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & InfantsCompletedNCT01262872Phase 2Results posted
• Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic TreatmentCompletedNCT01235949Phase 4Results posted
• Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy InfantsCompletedNCT01204658Phase 2Results posted
• Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850ACompletedNCT01175083Phase 3Results posted
• Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in NigeriaCompletedNCT01153893Phase 3Results posted
• Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in VietnamCompletedNCT01153841Phase 3Results posted
• Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster DoseCompletedNCT01119625Phase 3Results posted
• Booster and Catch-up Vaccination With Vaccine GSK1024850ACompletedNCT01030822Phase 3Results posted
• Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese ChildrenCompletedNCT01027845Phase 3Results posted
• Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First VaccinationCompletedNCT00985751Phase 2Results posted
• Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in MaliCompletedNCT00985465Phase 3Results posted
• Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed ChildrenCompletedNCT00950833Phase 3Results posted
• Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same VaccineCompletedNCT00911144Phase 3Results posted
• Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™CompletedNCT00907777Phase 3Results posted
• Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young AdultsCompletedNCT00896064Phase 2Results posted
• Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive DiseaseCompletedNCT00861380Phase 3Results posted
• Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850ACompletedNCT00839254Phase 3Results posted
• Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.CompletedNCT00829010Phase 3Results posted
• Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of AgeCompletedNCT00814710Phase 3Results posted
• Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of AgeCompletedNCT00808444Phase 3Results posted
• Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850ACompletedNCT00792909Phase 3Results posted
• Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™CompletedNCT00680914Phase 3Results posted
• Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™CompletedNCT00678301Phase 3Results posted
• Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/HibCompletedNCT00652951Phase 3Results posted
• Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate VaccineCompletedNCT00624819Phase 3Results posted
• Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.CompletedNCT00609492Phase 3Results posted
• Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same VaccinesCompletedNCT00547248Phase 3Results posted
• Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up ScheduleCompletedNCT00513409Phase 2Results posted
• Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850ACompletedNCT00496015Phase 3Results posted
• Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of AgeCompletedNCT00489554Phase 3Results posted
• COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate VaccineCompletedNCT00466947Phase 3Results posted
• Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm InfantsCompletedNCT00390910Phase 3Results posted
• Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.CompletedNCT00370396Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate VaccineCompletedNCT00345358Phase 3Results posted
• Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate VaccineCompletedNCT00344318Phase 3Results posted
• Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose ScheduleCompletedNCT00307034Phase 3Results posted
• Healthcare Seeking Behaviour of Primary Caregivers for Acute Otitis Media (AOM) in Children Aged 6 Months to Less Than 30 Months in PanamaCompletedNCT01793857
• Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in ToddlersCompletedNCT01485406Phase 1
• To Evaluate the Incidence of Acute Otitis Media in Children in Five East European CountriesCompletedNCT01365390
• Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in KoreaCompletedNCT01248988
• Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Episodes in Young Children in Saudi ArabiaCompletedNCT01204385
• Study to Characterize and Identify Bacteria Causing Acute Otitis Media in Young Egyptian ChildrenWithdrawnNCT01160055
• Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in PhilippinesTerminatedNCT01046097
• Study to Identify and Characterize Bacteria Causing Acute Otitis Media in Young Children in TurkeyWithdrawnNCT01031329
• Evaluation of Pneumococcal Vaccine Formulations in ElderlyCompletedNCT00756067Phase 1
• Evaluation of Pneumococcal Vaccine Formulations in Young AdultsCompletedNCT00707798Phase 1
• A Study in Elderly Subjects With Pneumonia to Support the Development of Bacteriological Diagnostic AssaysCompletedNCT00637351
• Exploratory Study in Healthy Elderly Subjects to Collect Urine for Development of Assays to Detect S. PneumoniaeCompletedNCT00523770
• Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate VaccineCompletedNCT00370227Phase 3
• Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.CompletedNCT00334334Phase 3
• Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.CompletedNCT00333450Phase 3
• Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly PopulationCompletedNCT00327665Phase 1
• A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority StudyCompletedNCT00307554Phase 3
• Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate VaccineCompletedNCT00307541Phase 3
• A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate VaccineCompletedNCT00169481Phase 2